INTRODUCTION
The first recognized step in the coagulation of plasma in glass tubes via the so-called intrinsic pathway is the activation of Hageman factor (factor XII). In turn, activated Hageman factor converts another clotting factor, plasma thromboplastin antecedent (PTA, Factor XI) 1 to activated PTA, probably by an enzymatic process (1, 2) . Although human activated PTA has been highly purified and its properties studied extensively (3), similar separation of PTA, its precursor, has been more difficult to achieve. The present study concerns the separation of PTA and some of its properties. A persistent puzzle in our understanding of hemostasis has been the dearth of hemorrhagic symptoms in the great majority of patients with Hageman trait, the hereditary deficiency of Hageman factor (4) . One proposed hypothesis is that alternative mechanisms exist in blood through which PTA can become active in the absence of Hageman factor. To examine this possibility, several proteolytic enzymes such as thrombin, plasma kallikrein, and trypsin were tested for their ability to activate PTA.
Evidence will be presented that PTA can be changed to its activated form enzymatically by bovine trypsin, a phenomenon also reported by Wuepper (5) while these studies were in progress.
MATERIALS
Venous blood was drawn by gravity from the antecubital veins of normal human subjects, using a no. 15 platelet-deficient plasma separated by two successive centrifugations at 16 ,300 g for 20 min each. Citrated human plasma deficient in one or another clotting factor and bovine PTA-deficient plasma (6) were obtained as described earlier (7) . A standard pool of 25 normal human plasmas was prepared by an earlier method (8) .
Partially purified PTA was prepared from pools of approximately 1 liter of oxalated normal human plasma to which 100th vol of 0.01 M disodium ethylenediaminetetraacetic acid (EDTA) and 5 mg of hexadimethrine bromide (Polybrene, Aldrich Chemical Co., Inc., Milwaukee, Wis.) per ml were added. The Polybrene served to prevent activation of PTA during the early steps of purification. The plasma was adsorbed with 7 mg of tricalcium phosphate (J. T. Baker Chemical Co., Phillipsburg, N. J.) per ml for 10 min at room temperature, using a magnetic stirrer; this procedure reduced the plasma's content of prothrombin (factor II), Stuart factor (factor X), factor VII, and Christmas factor (factor IX). The calcium phosphate was removed by centrifugation at 16 ,300 g for 10 min. The supernatant plasma was fractionated with neutral ammonium sulfate (Merck Chemical Div., Merck & Co., Inc., Rahway, N. J.) solution, saturated at 4VC, and containing 0.0001 M EDTA and 0.05 mg of Polybrene per ml. The fraction soluble at 20% saturation and insoluble at 60% saturation was dissolved in 0.025 M tris (hydroxymethyl)-aminomethane-HC1 (Tris) buffer (pH 8.0 at 4°C), containing 0.05 M sodium chloride, 0.0001 M EDTA, and 0.05 mg Polybrene per ml, the dialyzed overnight against two changes of 20 vol of the same buffer. The dialyzed solution was centrifuged for 10 min at 16 ,300 g, and the precipitate was discarded. The clear supernatant fluid was divided in half, and each portion was applied to a 5 X 53 cm silicone-coated glass chromatographic column containing QAE-Sephadex A-50 (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.) previously equilibrated with 0.025 M Tris buffer (pH 8.0) containing sodium chloride, EDTA, and Polybrene, as described above. The columns were each eluted with 2 liters of equilibrating buffer, and approximately 14-ml fractions were collected in cellulose nitrate or polystyrene tubes at a rate of 50-70 ml/h. PTA-like material, in the precursor form, was present in those fractions that did not adhere to the columns and was separated from Hageman factor and plasminogen, which were eluted at higher ionic strength (Fig. 1) Approximately 12-14 ml of each sample was applied, and 14 ml fractions were collected at a flow rate of 50 ml/h. The tubes with the greatest caseinolytic activity, detected upon treatment with streptokinase, were pooled and concentrated in an Amicon cell, fitted with a PM-10 Diaflo membrane, to a volume of 74 ml. The concentrated plasminogen was dialyzed against 0.025 M Tris buffer containing 0.05 M sodium chloride, 0.0001 M EDTA, and 0.05 mg of Polybrene per ml and was applied to a 2.5 X 29 cm column of QAE-Sephadex A-50 previously equilibrated with the same buffer. The column was washed with 450 ml of the equilibrating buffer and then eluted with a linear salt gradient of 500 ml each of the starting buffer and 0.025 M Tris buffer containing 0.5 M sodium chloride, 0.0001 M EDTA, and 0.05 mg of Polybrene per ml. 6-ml fractions were collected at a flow rate of 20 ml/h. The plasminogen was eluted between 0.11 and 0.18 M sodium chloride and was separated from Hageman factor which was eluted at higher ionic strength. The tubes with greatest streptokinase-activable caseinolytic activity were pooled, precipitated with 60% ammonium sulfate, and dialyzed against barbital-saline buffer. This preparation had a specific activity of 10 Remmert and Cohen U/mg of protein (11) and had no detectable free plasmin activity. It contained trace amounts of Hageman factor (less than 0.005 U/ml) but no measurable PTA, Christmas factor, antihemophilic factor, Stuart factor, factor VII, proaccelerin, prothrombin thrombin, or fibrinogen.
Streptokinase-activated plasmnin was prepared by incubating 18 ml of partially purified human plasminogen (3.5 Remmert and Cohen U/ml) with 0.2 ml of streptokinase solution (20, Enzite-trypsin (0.40 U/mg), Enzite-chymotrypsin (0.98 U/mg), Enzite-papain (0.35 U/mg with 5 mM cysteine), EnZite-ficin (0.10 U/mg without cystein) and Enzite-aamylase (1.8 U/mg), all enzymes in insoluble form, were purchased from Miles Research Div., Miles Laboratories, Inc., Elkhart, Ind. The supporting medium in Enzite-aamylase was microcrystalline cellulose, while that of the other Enzite-enzymes were 0-(carboxymethyl)cellulose (CM-cellulose). These Enzite-enzymes were rehydrated in distilled water before use and suspended in barbital-saline buffer. Enzite-papain was washed with 0.005 M cysteine and 0.002 M EDTA and resuspended in barbital-saline buffer.
Sepharose-hexanedianine plasmin was prepared from partially purified streptokinase-activated plasmin by attachment to Sepharose 4B-hexadiamine by carbodiimide (12) . The Sepharose-hexanediamine-plasmin contained 0.35 Remmert and Cohen U/ml of suspension.
Partially purified Hagemtan factor was prepared from normal human oxalated plasma by tricalcium phosphate adsorption, ammonium sulfate fractionation (20-60% saturation), and successive column chromatography on QAESephadex A-5O, DEAE-Sephadex A-50, Sephadex G150, and SP-Sephadex C-50.2 The batch used for the experiment of the effect of trypsin on Hagemen factor had a specific activity of 31 U/mg of protein (1 U being that amount found in 1 ml of a standard pool of normal human citrated plasma).
Barium carbonate-activated Hagemani factor was prepared by an earlier method (13). 2 ml of partially purified Hageman factor from the Sephadex G-150 step (10.5 U/ml, 3 U/mg protein) was mixed with 60 mg barium carbonate (Merck & Co., Inc.) in polystyrene tubes at 0°C for 10 min. The mixture was centrifuged at 2500 g for 5 min, and the separated precipitate was washed three times with barbital-saline buffer. The washed precipitate was dissolved in 1 ml of 1 N acetic acid and dialyzed against 300 ml of barbital-saline buffer for 3 h.
Partially purified human kallikrein was prepared from pools of approximately 500 ml of normal human-oxalated plasma. Oxalated plasma was adsorbed with 10 mg of tricalcium phosphate/ml for 10 min at 4°C. The calcium phosphate was removed by centrifugation, Celite 512 (20 mg/ml, Johns Manville Products Corp., Celite Div., Denver, Colo.) was added to the plasma, and the mixture was stirred for 10 min. The Celite was separated by filtration on a Buchner funnel, and washed repeatedly with distilled water to remove unabsorbed protein, and then eluted by the repeated addition of small volumes of 0.05 M Tris buffer (pH 8.0) containing 10% sodium chloride. The eluate, about the same volume as that of the original plasma, was concentrated to approximately 50 ml in an Amicon ultrafiltration cell using PM-10 Diaflo membrane and was dialyzed against 2 liters of 0.15 M sodium acetate buffer (pH 5.2). The dialyzed eluate was applied to a column of CM-Sephadex C-50 (2.5 X 30 cm, Pharmacia Fine Chemicals Inc.) equilibrated with 0.15 M sodium acetate buffer (pH 5.2). After the column was washed with approximately 120 ml of 0.067 M sodium phosphate buffer (pH 6.0), a linear gradient of 500 ml each of 0.067 M sodium phosphate buffer (pH 6.0) and the same buffer in 0.5 M sodium chloride was started, and approximately 5-ml fractions were collected. After approximately 50 tubes, two peaks of TAME-esterase activity were eluted: the first contained very little activated PTA activity, whereas the second had most of the activated PTA activity. The first TAME-esterase peak was concentrated 2 Saito, H., and 0. D. Ratnoff, unpublished data. Trypsin Activation of Plasma Thromboplastin Antecedent 853 in an Amicon cell, fitted with a PM-10 Diaflo membrane, and dialyzed against 0.025 M Tris buffer (pH 8.0) containing 0.0001 M EDTA. The dialyzed solution (approximately 63 ml) was applied to a column of QAE-Sephadex A-50 (2.5 X 32 cm) previously equilibrated with that same buffer. The column was eluted with the starting buffer, and material possessing TAME-esterase activity, which was present in those fractions which did not adhere to the column, was concentrated to approximately 100 ml in an Amicon cell using PM-10 membrane. This preparation released 1.1 juM methanol/ml per h in the TAME-esterase assay (specific activity: 60 gM/mg protein per h) and, on the average, 120 ng of bradykinin in the rat uterus assay. It contained trace amount of activated PTA activity (less than 0.01 U/ml) and Hageman factor cofactor but no measurable amount of Hageman factor, Christmas factor, thrombin, plasmin, and plasminogen.
Partially purified CY (an esterase derived from the first component of complement) was prepared by a method described earlier (14) . The preparation formed a single band on analytic disc gel electrophoresis and was free of any measurable amount of any of the known clotting factors. It contained 8.6 U/ml, as tested upon a substrate of Nacetyl-L-tyrosine ethyl ester (15 Crude kininogen for the assay of kallikrein-like activity was prepared by incubating normal human plasma, kept from contact with glass, at 61°C for 60 min to destroy its content of Hageman factor and plasma prekallikrein; the plasma was centrifuged, and the supernatant fluid was stored in polyethylene containers at -200C.
Bradykinin, the gift of Sandoz, Inc., Hanover, N. J., was dissolved at a concentration of 1 jug/ml in 0.15 M sodium chloride solution and stored at -200C in cellulose nitrate tubes. Before use, it was diluted appropriately in similar tubes.
O-phenanthroline (Fisher Scientific Co., Inc., Pittsburgh, Pa.) was dissolved at a concentration of 0.01 M in barbitalsaline buffer and stored at 40C.
Gliddex-P, a crude preparation of soybean phosphatides (the gift of the Glidden Paint Co., Chicago, Ill.) was prepared as a 0.1% suspension in 0.15 M sodium chloride solution and stored at -20'C until needed.3
Kaolin (acid-washed, N.F., Fisher Scientific Co., Inc.), chiefly aluminum hydrate, was suspended in the appropriate buffer with the aid of a mechanical homogenizer. KaolinGliddex, used to measure the concentration of clotting factors in the intrinsic pathway of thrombin formation, was a mixture of 50 mg of kaolin suspended in 5 ml of 0.1%o
Gliddex-P.
Barbital-saline buffer was 0.025 M barbital in 0.125 M sodium chloride (pH 7.5).
Carboxymethylcellulose (CM-cellulose) was obtained in microgranular, preswollen form from H. Reeve Angel & Co., Inc., Clifton, N. J., and Sepharose 4B was purchased from Pharmacia Fine Chemicals, Inc.
Silicone-coated glassware, including chromatographic columns, or plastic apparatus was used unless otherwise noted. The glassware was coated with silicone (Dri-Film SC-87, Pierce Chemical Co., Rockford, Ill.) and rinsed thoroughly with tap water and then distilled water, and the water was evaporated before use.
METHODS
Assay of PTA was performed by a reported method (3) . In essence, the sample was diluted appropriately in barbitalsaline buffer usually more than 20 times, since the presence of Polybrene (0.05 mg/ml) in some PTA preparations did not interfere with the assay of PTA at a 1: 20 dilution, and was incubated with kaolin-Gliddex and a substrate of human or bovine PTA-deficient plasma for 8 min at 370C in 10 X 75-mm glass tubes. The mixture was then recalcified, and the clotting time was measured at 370C. The (17) . Plasminogen and plasmin were assayed by caseinolytic activity with and without streptokinase by a modification of the method of Remmert and Cohen (11) .
Hagemwan factor-cofactor was assayed by a method previously described (18) .
The fibrinolytic activity of partially purified PTA was 'estimated by mixing 0.1 ml of PTA (2 U/ml) with 0.025 ml of streptokinase (20,000 Christensen U/ml), 0.2 ml of 713"% bovine fibrinogen solution and 0.1 ml of partially puri-.fied bovine thrombin (40 NIH U/ml) in 10 X 75-mm polystyrene tubes. The resultant clots were incubated at 37°C and inspected for fibrinolysis.
The presence of IgG was tested by immunodiffusion in 0.9% agarose gel against goat antiserum to human IgG for 2 days at room temperature. TAME-esterase activity was measured by a minor modification of Siegelman's method (Siegelman, Carlson, and Robertson 19) . A sample of 0.25 ml was incubated at 370C with 2.5 ml of 0.015 M TAME in 0.067 M sodium phosphate buffer (pH 7.5) containing 0.6% NaCl. After 1 and 61 min, 1-ml aliquots were withdrawn and transferred to glass tubes containing 0.5 ml of 0.75 M perchloric acid. In succession, 0.1 ml of a 2% aqueous potassium-permanganate solution, 0.1 ml of 10% aqueous sodium bisulfite solution, and 4.0 ml of chromatropic acid "working reagent" were added to the assay tubes. The color evolved after heating the tubes in a boiling water bath for 15 min was measured at 580 nm. The color was compared with that of a freshly prepared standard of methanol in phosphate-saline buffer, assayed in the same way. The results were expressed as micromoles of methanol released/milliliter per hour.
Kallikrein-like activity was estimated by incubating a mixture of 0.1 ml of 0.01 M O-phenanthroline solution, 0.1 ml of crude kininogen, 0.1-0.6 ml of sample to be tested, and sufficient barbital-saline buffer to bring the volume to 1.0 ml in polystyrene tubes for 15 min at 37°C. The effect of portions of this mixture was then tested on the estrus rat uterus in comparison with a bradykinin standard as described earlier (20) .
The activation of PTA by trypsin was studied by the following methods. After 0.1 ml of PTA (1.7 U/ml) and 0.1 ml of trypsin (0.1 mg/ml) were incubated at 37°C, the trypsin was inhibited by the addition of 0.1 ml of LBTI (0.33 mg/ml). The mixture was then assayed on substrates of PTA-deficient or Christmas factor-deficient plasma; 0.1 ml of the solution to be tested, 0.1 ml of Gliddex-P and 0.1 ml substrate plasma were mixed in a 10 X 75 mm polystyrene tube, and after incubation for 1 min at 37°C, 0.1 ml of 0.025 M CaCl2 was added and the clotting time was measured. The concentration of LBTI used was sufficient to inhibit tryptic activity, but did not interfere with the clotting assay for activated PTA. The effect of varying the concentration of trypsin on PTA activation was studied by incubating different amounts of trypsin with a constant amount of PTA. At intervals, portions of this mixture were removed, and LBTI was added, and the mixture tested for activated PTA. The effect of varying the concentration of PTA on PTA activation was investigated by incubating different amounts of PTA with a constant quantity of trypsin. After inhibition of the trypsin with LBTI activated PTA was assayed.
The effect of insolubilized en.vvymies on PTA'4 was studied by incubating 0.3 ml of partially purified PTA and 0.2 ml of a suspension of a water-insoluble enzyme (Sepharoseplasmin, Enzite-trypsin, Enzite-chymotrypsin, Enzite-papain, Enzite-ficin, or lhzite-amylase) in a 10 X 75 mm polystyrene tube at 370C, with the occasional stirring. At intervals, the tubes were centrifuged At 80t g for 5 min at 20C, arid the supernatant fluid was separated from the precipitated enzyme, using a silicone-coated glass dropper. The supernatant fluid was immediately tested on PTA-deficient, Hageman factor-deficient, or Christmas factor-deficient plasma, as described above.
The effect of trypsinl ont the clot-promnoting property of Hageonawt factor was studied by incubating equal volumes of partially purified Hageman factor (0.4 U/ml) and trypsin (0.05 mg/ml) at 370C. At intervals, portions were tested for both Hageman factor and activated Hageman factor activity after inhibiting trypsin by LBTI. Assay of activated Hageman factor was performed by incubating sample with Gliddex and Hageman factor-deficient plasma in 10 X 75 mmpolystyrene tubes at 370C for 8 min. The contents were then recalcified, and the clotting time was measured at 370C.
The effect of temiperature o07 PTA activation by trypsin was studied as follows: 0.1 ml of PTA (1.7 13/ml) and 0.1 ml of trypsin (0.1 mg/ml) were incubated for 10 nin at varying temperatures, after which the action of trypsin was stopped by adding 0.1 ml of LBTI (0.33 mg/nil). The mixtures were then assayed for activated PTA-like activity. A standard curve was prepared by testing serial dilution of the mixture incubated at 370C. The results were expressed as the per cent of PTA-like activity generated relative to that evolving at 370C (100%).
The effect of specific rabbit autiserumis upon trypsinactivated PTA-like activity was tested by incubating 0.1 ml of Enzite-trypsin-or soluble trypsin-activated PTA with 0.1 ml of absorbed, treated antiserum, against PTA, Hageman factor, or similarly treated normal rabbit serum for 30 min at 370C in 10 X 75-mm polystyrene tubes. A 0.1 ml aliquot was then tested for activated PTA-like activity by the method described above. A standard curve was made by testing serial dilution of trypsin-activated PTA incubated with normal rabbit serum in 0.1% bovine albumin in barbital-saline buffer.
The effect of throinbin o01 PTA was studied by incubating equal volumes of PTA (2 U/ml) and human thrombin (1.2 U/ml) or partially purified bovine thrombin (2 U/ml) in 10 X 75-mm polystyrene tubes at 370C. At intervals, portions were tested for activated PTA activity after inhibiting thrombin by hirudin equivalent to the thrombin used.
The effect of plasma kallikreiui on PTA was studied by incubating equal volumes of PTA (2 U/ml) and kallikrein (1.1 ,uM methanol released/ml per h) at 370C in 10 X 75-mm polystyrene tubes. At intervals, portions were tested for activated PTA activity using bovine PTA-deficient plasma as the substrate. As a control, PTA was incubated with trypsin (0.1 mg/ml) and was tested in the same wav after inhibition of trypsin with LBTI (0.33 mg/ml).
The effect of Ci onl PTA was studied by incubating equal volumes of PTA (1.7 U/ml) and CT (8.6 U/ml) at 370C.
At intervals, portions were tested for activated PTA activity, using human PTA-deficient plasma as the substrate. In preliminary experiments, it was found that this amount of C1 did not interfere with the assay for activated PTA. Therefore, no inhibitor was used to stop Cl activity after incubation with PTA.
The effect of tissue thromboplastiin o)n PTA was studied by incubating 5 ml of partially purified PTA (1 U/ml) or barbital-saline buffer at 370C for 20 miii with 1 mg/ml of rabbit or human brain tissue thromboplastin, previously washed with barbital-saline buffer. The tissue thromboTrypsin Activation of Plasma Thromboplastin Antecedent 855 plastin was then sedimented by ultracentrifugation at 130,-000 g for 2 h at 2°C. The clear supernate was removed and tested for activated PTA-like activity. In experiments using purified human placental tissue thromboplastin and crude human brain tissue thromboplastin obtained from Dr. F. Pitlick, PTA was incubated with these thromboplastins in imidazole-saline buffer (pH 6.8) for 90 min at 37°C.
A crude estimation of molecular weight of unactivated PTA, Hageman factor-activated PTA, and trypsin-activated PTA was obtained by applying 3 ml of sample in 1% bovine albumin (the latter used as an internal marker) to a 2.6 X 100 cm column of Sephadex G-150 equilibrated with 0.025 M Tris-HCl buffer (pH 8.0 at 4°C) containing 0.15 M NaCl and 0.0001 M EDTA. The column was eluted with the same buffer at the flow rate of 10-15 ml/h, and 3 ml-fractions were collected. Fractions were tested for PTA and activated PTA activity. As markers, Blue dextran 2000 (Pharmacia Fine Chemicals, Inc.) and the following proteins were used: 1% bovine gamma globulin (Armour Pharmaceutical Company, mol wt 160,000), 1% rabbit muscle aldolase (Worthington Biochemical Corp., mol wt 158,000), 1% yeast alcohol dehydrogenase (Worthington Biochemical Corp., mol wt 151,000), 0.1 ml/ml of Escherichia coli alkaline phosphatase (Worthington Biochemical Corp., mol wt 80,000), 1% bovine albumin (Armour Pharmaceutical Co., mol wt 67,000), 1% ovalbumin (Schwarz/Mann Div., Becton, Dickinson & Co., Orangeburg, N. Y., mol wt 45,000).
rhe peak of maximal elution of these markers were read at OD 280 nm except for alkaline phosphatase, which was assayed on a substrate of disodium p-nitrophenyl phosphate (ICN Nutritional Biochemicals Div.) (21) . The molecular weight of PTA and activated PTA were estimated by using Andrews' assumption that a linear relationship exists between the logarithm of molecular weight and elution volume (22) . A regression line was drawn, using the method of least squares and the molecular weights of PTA and activated PTA were read by extrapolation. This estimation makes the unproved assumption that the molecules tested are spheroidal.
Protein was determined by the method of Lowry, Rosebrough, Farr, and Randall (23) and was estimated more crudely by absorption at 280 nm using a Beckman model DU Spectrophotometer.
Dialyses were performed at 40C in cellophane casings (VisKing Corp., Chicago, Ill.) prepared by boiling in 0.0001 M EDTA, followed by thorough washing in distilled water.
Centrifugations were carried out at 20C in an International PR-2 refrigerated centrifuge (International Equipment Co., Boston, Mass.) and at high speeds in a Servall RC-2 refrigerated centrifuge unless otherwise noted.
RESULTS
PTA activation by trypsin. When partially purified unactivated PTA was first incubated with trypsin and tryptic action was then inhibited by LBTI, a clot-promoting agent was found which shortened the clotting time of PTA-deficient plasma, but not that of Christmas factor-deficient plasma (Table I ). No such activity was found when trypsin was inhibited by LBTI before its addition to PTA, or when PTA alone was incubated.
The generation of a clot-promoting agent from PTA by trypsin was confirmed by an alternative method in which the insolubilized trypsin was used. Incubation of PTA with Enzite-trypsin resulted in the time-dependent generation of an agent that shortened the clotting time of PTA-deficient or Hageman factor-deficient plasma but not that of Christmas factor-deficient plasma. On the contrary, the incubation of either PTA, Enzitetrypsin alone, or PTA with CM-cellulose did not induce this property (Table II) . These data suggest that activated PTA-like activity was generated from precursor PTA by the action of trypsin. Since the same results were obtained with either human or bovine PTA-deficient plasma as substrate in the activated PTA assay, bovine PTA-deficient plasma was used in most of the following studies.
The way in which trypsin converts PTA to its activated form was investigated by varying the concentration of either trypsin or PTA and studying the effect of PTA + Trypsin, 370C 10 min LBTI 0C 3 min 60.9 (100%)* >400 PTA + Buffer, 370C 10 min Buffer 0C 3 min 358.6 (<1%)* >400 LBTI + Trypsin, 0C 3 min PTA 370C 10 min 232.6 (<I%)* >400 LBTI + Trypsin, 0C 3 min Buffer 370C 10 min >400 (<1%)* >400 0.1 ml each of PTA (1.7 U/ml), trypsin (0.1 mg/ml), and LBTI (0.33 mg/ml) were added and incubated in the sequence shown above in 10 X 75-mm polystyrene tubes. 0.1-ml aliquots of mixtures were then assayed on substrates of PTA-deficient plasma or Christmas factor-deficient plasma as described in Methods. * Expressed as the percent of the clot-promoting activity relative to that of the sample with the greatest activity. Mixtures of 0.3 ml PTA (2.4 U/ml) and 0.2 ml of each agent or barbital-saline buffer were incubated at 370C with the occasional stirring for the time indicated and then centrifuged at 800 g. for 5 min at 20C. The supernatant fluid was removed with silicone-coated glass droppers and immediately tested on bovine PTA-deficient plasma, Hageman factor-deficient plasma or Christmas factor-deficient plasma as described in Methods.
these maneuvers on the evolution of activated PTA-like activity. When the concentration of trypsin was varied over a fourfold range and the concentration of PTA was kept constant, the yield of clot-promoting activity (presumably due to activated PTA-like) was essentially the same (Fig. 4) . On the other hand, when the concentration of PTA was varied over a 13-fold range and that of trypsin was kept constant, the yield varied in proportion to the initial concentration of PTA (Fig.  5 ). These data suggest that trypsin generates clot-promoting activity from PTA enzymatically. When partially purified, unactivated Hageman factor was incubated with trypsin under the same conditions and was U/ml) and 0.3 ml of trypsin (0.1, 0.05, or 0.025 mg/ml) were incubated at 37°C in 10 X 75-mm polystyrene tubes. At intervals, portions of this mixture were removed and the tryptic action was stopped by the addition of LBTJ.
60-100%
The mixture was then tested for activated PTA, using bovine PTA-deficient plasma as a substrate.
tested on Hageman factor-deficient plasma, no significant clot-promoting activity was generated. The clotpromoting activity of the Hageman factor preparation evolved upon contact with glass decayed during its incubation with trypsin, a result consistent with that reported by Soltay, Movat, and Ozge-Anwar (24) . These data suggest that clot-promoting activity was evolved from PTA by trypsin enzymatically and that this PTA activation was not via Hageman factor activation. As discussed in a previous paper (3), no valid comparison can be made between the assay for PTA and activated PTA. Were the assumption made that such a comparison was possible, approximately all the PTA was converted into its active form by trypsin. 62.0 100 0.1 ml of PTA (1.7 U/ml) and 0.1 ml of trypsin (0.1 mg/ml) were incubated for 10 min at varying temperature. The trypsin was inhibited by the addition of 0.1 ml of LBTI (0.33 mg/ml) and portions were assayed for activated PTA-like activity, using bovine PTA-deficient plasma as substrate, as described in Methods. The results were expressed as the clotting time and as the percent of activated PTA-like activity generated relative to that evolving at 370C (100%).
Effect of temperature upon the PTA activation by trypsin. The rate at which activated PTA-like activity generated in a mixture of PTA and trypsin was temperature dependent (Table III) Hageman factor antiserum, undiluted -> 500 0.3 ml of PTA (4 U/ml) and 0.3 ml of trypsin (0.1 mg/ml) were incubated at 370C for 10 min, and trypsin was inhibited by the addition of 0.3 ml of LBTI (0.5 mg/ml). (Fig. 6 ). This adds evidence that the clot-promoting agent evolved from PTA by trypsin was activated PTA. These experiments indicated that the conversion of PTA to clot-promoting agent does not appreciably alter the size of PTA under these conditions. This result is in good agreement with that of Donaldson and Ratnoff by sucrose density gradient centrifugation (13) and the more recent study of Ratnoff (16) by gel filtration on Sephadex G-150, in which crude PTA prepared from Hageman factor-deficient plasma was used. DISCUSSION PTA is the inert precursor of a clot-promoting agent participating early in the intrinsic pathway of thrombin formation in mammalian plasma. It is generally agreed that activated Hageman factor converts PTA to its activated form enzymatically and triggers a chain-reaction terminating in a solid fibrin formation. However, the absence of a bleeding tendency in Hageman factordeficient patients suggests that under some conditions PTA can become active in the absence of Hageman factor. Since the mechanism(s) of PTA activation by activated Hageman factor may be a limited proteolysis, several proteolytic enzymes including thrombin, plasmin, plasma kallikrein, and trypsin were tested for their possible ability to activate PTA. The experiments reported here provide support for the view that PTA can be activated by trypsin. Preparations of PTA purified approximately 4500-fold over normal human plasma.
and devoid of detectable amounts of other clotting factors, generated potent clot-promoting activity when incubated with trypsin. The agent that evolved behaved like activated PTA, for it corrected the abnormally long clotting time of plasma deficient in Hageman factor or PTA but not plasma deficient in Christmas factor. Moreover, the clot-promoting agent behaved like activated PTA upon gel filtration through Sephadex G-150 and was specifically inhibited by an antiserum directed against activated PTA. No evidence was obtained that suggested that the effect of trypsin was indirect, through an action upon Hageman factor contaminating the preparation of PTA. The absence of appreciable amounts of Hageman factor in such preparations was established both in clotting and immunologic assays. Further, no activation of the clot-promoting properties of Hageman factor was noted upon incubation with trypsin. The clot-promoting activity of the Hageman factor preparation evolved upon contact with glass decayed during its incubation with trypsin. These results also exclude the possibility that the preparation of trypsin used for PTA activation could have been contaminated with Hageman factor which might activate PTA. Several groups of investigators have reported that a low molecular weight (30.-000-40,000 D) anionic substance (prealbumin or prekallikrein activator) can be derived from Hageman factor through treatment with plasmin or trypsin (24, 27, 28) . This substance activates prekallikrein but has only about 1/50th the clot-promoting activity compared with the parent Hageman factor. The present study does not bear upon the formation of the prekallikrein activator but does confirm the inability of trypsin to induce formation of clot-promoting activity from Hageman factor.
Trypsin Activation of Plasma Thromboplastin Antecedent
No evidence was obtained that autocatalytic activation of PTA could be induced by activated PTA, nor was activation brought about by incubation with human or bovine thrombin, plasma kallikrein, papain, plasmin, ficin, chymotrypsin, tissue thromboplastin, Cl, or aamylase.
The activation of PTA by trypsin appeared to be enzymatic. The reaction was temperature dependent, the rate of generation of activated PTA was dependent upon the concentration of enzyme added, and the yield of activated PTA was a function of the concentration of PTA. Whatever the effect of trypsin, it was not associated with a major change in the molecular weight of PTA, as tested by gel filtration. This observation confirms earlier studies from this laboratory, using ultracentrifugation (13) and gel filtration (16) . Presumably, the change in molecular size is too small to be measured in these crude ways, or, alternatively, the cleaved fragment or fragments do not completely separate from the parent molecule of PTA under the conditions used.
The present study was made feasible by the use of LBTI, an inhibitor of trypsin. In this situation, the enzyme must be neutralized by the addition of LBTI before clotting assays can be performed. The results of our studies were, therefore, confirmed through the use of insolubilized trypsin which can be removed from the reaction mixture before assays for clot-promoting activity are undertaken. Such water-insoluble enzymes have the disadvantage that they tend to exclude macromolecules because of the structure of the insoluble carrier, and may be, therefore, less active upon protein substrates compared with its soluble form.
Since only trace amounts of trypsin were necessary to activate PTA, the possibility exists that the enzyme may carry out this function within the body. Under normal conditions, trypsin cannot be detected in mammalian blood. Perhaps, however, trypsin may be released into the blood stream under pathologic conditions, such as pancreatitis, and can then activate PTA as well as Stuart factor and prothrombin, two other known substrates (29) .
The experiments described lend some support to the view that the absence of hemorrhagic symptoms in Hageman trait bespeaks the presence of an alternative mechanism for initiation of clotting via the intrinsic pathway. The nature of the proteolytic enzyme responsible for activation of PTA in the absence of Hageman factor remains to be determined. It should be noted, however that other explanations for the absence of bleeding symptoms in Hageman trait are possible. For example, Nemerson and Pitlick (30) proposed recently that low or immeasurable levels of Hageman factor may be concentrated to hemostatically effective levels by their high affinity for damaged tissue.
